A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Vancomycin Pre-Treatment

Four times daily dosing with Vancomycin

DRUG

Vancomycin Placebo

Four times daily dosing with Vancomycin Placebo

DRUG

SER-155

Once daily dosing with SER-155

DRUG

SER-155 Placebo

Once daily dosing with SER-155 placebo

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

21044

Georgetown (MedStar Health), Washington D.C.

27514

University of North Carolina Chapel Hill, Chapel Hill

32224

Mayo Clinic - Jacksonville, Jacksonville

32610

University of Florida - Division of Hematology & Oncology, Gainesville

55905

Mayo Clinic - Rochester, Rochester

60637

University of Chicago Medical Center, Chicago

85234

Banner Health - MD Anderson Medical Center, Gilbert

85259

Mayo Clinic - Scottsdale, Scottsdale

90292

University of California, Los Angeles - Division of Hematology-Oncology, Marina del Rey

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

Harvard Medical School - Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Seres Therapeutics, Inc.

INDUSTRY

NCT04995653 - A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT | Biotech Hunter | Biotech Hunter